Insight2021-03-21T16:52:20+00:00
Loading...

Latest news and thought leadership

All the latest from Deallus pharmaceutical and life science industry experts

CARe To Understand What Will Shape CAR T’s Future?

March 16th, 2021|Categories: Thought Piece, White Paper|Tags: , , |

CAR T-cell therapies space is complex, highly competitive, and quickly evolving. Add the pandemic to the mix and the logistical, reimbursement, and pricing landscape grows even more complicated. In this in-depth paper we research the current state of CAR T-cell therapies and speculate on the factors currently making the largest impact - China, Commercialization, and COVID-19. Read more for a comprehensive, well-researched take on the space.

OnDemand Webinar – Leading in a crisis

February 2nd, 2021|Categories: News, Thought Piece, Video|Tags: , |

Peter Hempshall, Deallus CEO, and Rita Numerof, President & Co-Founder of Numerof & Associates, have joined forces to generate thought-provoking discussion series on Navigating Market Disruption. Episode two is Leading in a crisis. Rita and Pete will discuss why focus and remaining agile during and after a crisis are essential for success. Executives looking for practical advice on how to balance agility and governance processes will find this discussion valuable.

Kevin Bibby joins Deallus as Senior Principal

January 5th, 2021|Categories: News|

We are very pleased to welcome Kevin Bibby to our Deallus team as Senior Principal. Kevin brings extensive expertise in commercial strategy to the fold, as well as a deep background in brand and portfolio strategy, product positioning, and workshop facilitation. We look forward to adding his knowledge, skill sets, and collaborative spirit to the team.

Episode 2: Leading in a crisis

September 14th, 2020|Categories: News|Tags: , |

Join Peter Hempshall, Deallus CEO, and Rita Numerof, President of Numerof & Associates for Episode 2 of their discussion series - Leading in a crisis. This episode will explore topics around how leaders can manage effectively during a crisis and continue to deliver value for their customers, their organizations, and for themselves. Any business leader eager to explore tactics, best practices, and learning experiences gained from leading in times of uncertainty will find value in this episode.

OnDemand Webinar – Navigating Market Disruption after COVID-19

September 3rd, 2020|Categories: News, Thought Piece, Video|Tags: , |

Peter Hempshall, Deallus CEO, and Rita Numerof, President & Co-Founder of Numerof & Associates, have joined forces to generate thought-provoking discussions on ‘Navigating Market Disruption After Covid-19’. This OnDemand webinar discusses how the pandemic has accelerated market shifts already in play, disrupting current business models, and dramatically altering how pharma business will be done in the future.

Deallus Virtual Workshop on Competitive Insight at EyeforPharma 2020

September 3rd, 2020|Categories: News, Video|Tags: |

What is a ‘competitive insight’? How do you make it actionable? These were the two key questions we focused on at EyeForPharma. Competitive Insights are the secret sauce that generate Competitive Advantage from Strategic Intelligence and point to opportunities of impact where it matters most. We offered participants a compressed but unique hands-on experience of generating competitive insights and focused on understanding how to make them truly actionable.

CARe To Understand What Will Shape CAR T’s Future?

CAR T-cell therapies space is complex, highly competitive, and quickly evolving. Add the pandemic to the mix and the logistical, reimbursement, and pricing landscape grows even more complicated. In this in-depth paper we research the current state of CAR T-cell therapies and speculate on the factors currently making the largest impact - China, Commercialization, and COVID-19. Read more for a comprehensive, well-researched take on the space.

March 16th, 2021|Categories: Thought Piece, White Paper|Tags: , , |

The Future of JAK Inhibitors

From blockbuster drugs to black box warnings, Janus kinase inhibitors (JAKs) have seen dramatic highs and lows in their journey to market access across the last few years. Yet despite the hurdles, JAKs are facing, pharma’s conviction in their potential to generate a paradigm shift in patient care means R&D activity and interest remains undaunted. Will JAK inhibitors triumph over persisting regulatory roadblocks to offer patients a new treatment option? In this white paper, we investigate the current state of JAKs and explore their likelihood of success in the future.

January 6th, 2020|Categories: White Paper|Tags: , , |

Digitizing Healthcare

Healthcare has always had a reputation of being resistant to change, but consumer demand and a rapidly evolving technology-driven world have led the digitization of healthcare to move at a frantic pace. In this white paper we explore the digitization trend currently infiltrating healthcare and delve into the implications of digital health on patients, payers, and pharma itself. We take stock of the current landscape, discuss likely future trends, and explore how strategic intelligence can help answer key questions for the healthcare industry in the face of so much digital innovation.

December 18th, 2019|Categories: White Paper|Tags: , |

OnDemand Webinar – Leading in a crisis

February 2nd, 2021|Categories: News, Thought Piece, Video|Tags: , |

Peter Hempshall, Deallus CEO, and Rita Numerof, President & Co-Founder of Numerof & Associates, have joined forces to generate thought-provoking discussion series on Navigating Market Disruption. Episode two is Leading in a crisis. Rita and Pete will discuss why focus and remaining agile during and after a crisis are essential for success. Executives looking for practical advice on how to balance agility and governance processes will find this discussion valuable.

OnDemand Webinar – Navigating Market Disruption after COVID-19

September 3rd, 2020|Categories: News, Thought Piece, Video|Tags: , |

Peter Hempshall, Deallus CEO, and Rita Numerof, President & Co-Founder of Numerof & Associates, have joined forces to generate thought-provoking discussions on ‘Navigating Market Disruption After Covid-19’. This OnDemand webinar discusses how the pandemic has accelerated market shifts already in play, disrupting current business models, and dramatically altering how pharma business will be done in the future.

Competitive Simulation Strategy

Tags: , , , |

Our client was facing a major pharma player in a highly lucrative and rare disease space. They wanted to ensure that they had a chance to analyze their competition’s launch plan and plans for targeting their own product, but they did not have the time to conduct a cross-functional, traditional workshop. They came to us to discuss their goals and assess the most strategic way forward. This case study explores this launch scenario in which we put a unique spin on the traditional competitive simulation approach for our client.

Launching for Success

Tags: , , , |

Our client was a small-to medium-sized pharmaceutical company with a limited development pipeline who was in the process of launching their first product, an orphan drug, for treating a rare disease. They were a relatively small organisation with no prior knowledge of the competitive environment and no standardised launch planning process or procedures. This case study explores how our client engaged us to help them understand their competitive landscape, streamline launch efforts across markets, and stress test and revise their launch planning strategies.

Asset Evaluation

Tags: , , , , |

Our client was a medium-sized pharma company interested in launching an antibiotic asset for treating pathogens with limited treatment options in Central and Southern Europe, as well as the Middle East. Their antibiotic was a particularly strong candidate for commercialization due to its novelty in tackling multi-resistant antibiotic pathogens and the extremely high unmet demands in the targeted regions. Our client engaged us to work with their business intelligence managers in order to evaluate the commercial value of the asset and to advise on the best strategic route to commercialization.

Pharma CI US 2020

Sponsors at Pharma CI US

Sept 29 – Oct 1, 2020
VIRTUAL EVENT

Learn more
PharmaCI Europe 2020

Sponsors at PharmaCI Europe

July 1-2, 2021
Zurich, Switzerland

Learn more

Register your email address to be alerted to our latest news

    Go to Top